Carbogen Amcis, a Bubendorf, Switzerland-based CDMO of active pharmaceutical ingredients (API) and drug products, has announced plans to invest over CHF 100 million ($110 million) for two new manufacturing facilities in Switzerland and France. The two new facilities will be phased in over the next four years (as reported on August 17, 2020).

In Switzerland, the project will be initiated in 2021 with construction of a new API manufacturing facility at the company’s site in Hunzenschwil. The project will progress in several phases with the new facility expected to be operational by the summer 2024.

In addition to the new Swiss API manufacturing facility, additional investments are planned with a dedicated budget to improve some existing technologies and to increase capacity of the company’s current Swiss sites, such as adding chromatography equipment, new reactors in production, and new laboratories.

In France, on newly acquired land in proximity to the company’s existing site in Riom, construction will begin in January 2021 for a new facility dedicated to custom development and manufacturing of parenteral drug products. The facility will allow for the handling of complex formulations, including a large range of different types of APIs and highly potent compounds.

The new French site will be able to supply both clinical batches up to Phase III and small-scale commercial production. There will be two automated lines: the first one for liquid filling lyophilization, and a second line dedicated to liquid forms. In addition, development and analytical laboratories will be incorporated to support customer projects. Operations are slated to begin during the first quarter of 2023.

Source: Carbogen Amcis